The Cancer Research Continuum: Frustration to Hope

| No Comments

Sunday's New York Times had a pretty compelling profile on M.D. Anderson, its patients, and its staff (who can also become the hospital's patients).  Gina Kolata really captured how the path to remission is filled with dead-ends, experimentations, frustration--as well as hope.

 

I am always sort of amazed when people say we have to "cure cancer."  It just seems a bit reductive to me. Cancer is so elusive--it is not one disease, and each type of cancer does not behave the same way in each patient.  This complexity requires us to fight the war on many fronts.  Some cancers can be prevented, some can be managed, and some go into remission.  Innovation requires investment, and any type of progress is going to take the collaborative efforts of private enterprise, academia, and the government.

Leave a comment

BlogWithIntegrity.com
   Follow GSKUS on Twitter
Share this page with:
Twitter Twitter
Facebook Facebook
Digg Digg

About this Entry

This page contains a single entry by Michael M, GSK Communications published on October 26, 2009 3:18 PM.

Opportunities ... and Challenges (or, No One Said It Was Going To Be Easy) was the previous entry in this blog.

Collaboration in Action: GSK and the Redskins is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.